4D Molecular Therapeutics

4D Molecular Therapeutics

FDMT· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock -72.5% in FY2024

David Kirn, M.D. is the CEO of 4D Molecular Therapeutics and was paid $1.0M in FY2024 (Dec), down 90%.

Pay$100 in the stock at the end of FY21 → $25
CEO pay is from each 4D Molecular Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Kristian HumerFY2025
  2. 2Fariborz Kamal, Ph.D.FY2025
  3. 3David Kirn, M.D.FY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

4D Molecular Therapeutics paid its 2 named executives $5.4M in total in FY2025 (Dec).

Name
Kristian HumerChief Financial OfficerNot disclosedNot disclosed
Fariborz Kamal, Ph.D.Former Chief Operating Officer & President
David Kirn, M.D.President and Chief Executive OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for 4D Molecular Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board2

See all
  • Susannah Gray, MBADirector · 5 yr on the boardIndependentAudit (Chair), Compensation (Chair)—Paid as an executive
  • Glenn SblendorioDirector · -1 yr on the boardIndependentCompensation, Science and Technology—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KMar 18, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 10, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data